Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
Hospira, Inc. announced the acquisition of worldwide rights to a biogeneric version of filgrastim and an affiliated European manufacturing facility from PLIVA Hrvatska d.o.o., a move that will help extend Hospira's reach and vertical integration in biogenerics. Financial terms of the agreement were not disclosed.
As a result of the acquisition, Hospira will now have full global rights to the biogeneric filgrastim that had previously been part of a strategic collaboration between Hospira and PLIVA/Barr, the latter two companies now owned by Teva Pharmaceutical Industries Ltd.
As part of the agreement, Hospira has also acquired process development capabilities and a manufacturing plant inCroatia. The site has capacity sufficient to meet Hospira's worldwide filgrastim and pegfilgrastim requirements, along with expansion possibility for additional biogenerics manufacturing.
Applications for product approval of filgrastim were filed with the European Medicines Agency (EMEA) andAustralia'sTherapeutic Goods Administration (TGA) in the first quarter of 2009.
Filgrastim is a granulocyte colony-stimulating factor (G-CSF) used to treat neutropenia, a condition in which the body makes too few infection-fighting white blood cells. The condition is often caused by drugs prescribed for cancer treatment.
Other news from the department business & finance
